Literature DB >> 17297458

Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells.

S L Miller1, G Antico, P N Raghunath, J E Tomaszewski, C V Clevenger.   

Abstract

Prolactin (PRL) stimulates the cytoskeletal re-organization and motility of breast cancer cells. During PRL receptor signaling, Vav2 becomes phosphorylated and activated, an event regulated by the serine/threonine kinase Nek3. Given the regulatory role of Vav2, the function of Nek3 in PRL-mediated motility and invasion was examined. Overexpression of Nek3 in Chinese hamster ovary transfectants potentiated cytoskeletal re-organization in response to PRL. In contrast, downregulation of Nek3 expression by small-interfering RNA (siRNA) attenuated PRL-mediated cytoskeletal reorganization, activation of GTPase Rac1, cell migration and invasion of T47D cells. In addition, PRL stimulation induced an interaction between Nek3 and paxillin and significantly increased paxillin serine phosphorylation, whereas Nek3 siRNA-transfected cells showed a marked reduction in paxillin phosphorylation. Analysis of breast tissue microarrays also demonstrated a significant up-regulation of Nek3 expression in malignant versus normal specimens. These data suggest that Nek3 contributes to PRL-mediated breast cancer motility through mechanisms involving Rac1 activation and paxillin phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17297458     DOI: 10.1038/sj.onc.1210264

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

1.  Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells.

Authors:  Feng Fang; Jiamao Zheng; Traci L Galbaugh; Alyson A Fiorillo; Elizabeth E Hjort; Xianke Zeng; Charles V Clevenger
Journal:  J Mol Endocrinol       Date:  2010-03-17       Impact factor: 5.098

2.  The NIMA-family kinase Nek3 regulates microtubule acetylation in neurons.

Authors:  Jufang Chang; Robert H Baloh; Jeffrey Milbrandt
Journal:  J Cell Sci       Date:  2009-06-09       Impact factor: 5.285

3.  Src tyrosyl phosphorylates cortactin in response to prolactin.

Authors:  Alan Hammer; Sneha Laghate; Maria Diakonova
Journal:  Biochem Biophys Res Commun       Date:  2015-06-01       Impact factor: 3.575

Review 4.  In depth analysis of kinase cross screening data to identify chemical starting points for inhibition of the Nek family of kinases.

Authors:  C I Wells; N R Kapadia; R M Couñago; D H Drewry
Journal:  Medchemcomm       Date:  2017-12-08       Impact factor: 3.597

Review 5.  Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models.

Authors:  Katherine A Leehy; Thu H Truong; Laura J Mauro; Carol A Lange
Journal:  J Steroid Biochem Mol Biol       Date:  2017-04-23       Impact factor: 4.292

6.  Adapter protein SH2B1beta binds filamin A to regulate prolactin-dependent cytoskeletal reorganization and cell motility.

Authors:  Leah Rider; Maria Diakonova
Journal:  Mol Endocrinol       Date:  2011-05-12

Review 7.  Regulation of prolactin receptor levels and activity in breast cancer.

Authors:  G Swaminathan; B Varghese; S Y Fuchs
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

8.  Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer.

Authors:  Feng Fang; Ayanna J Flegler; Pan Du; Simon Lin; Charles V Clevenger
Journal:  Am J Pathol       Date:  2008-12-04       Impact factor: 4.307

9.  Autocrine prolactin: an emerging market for homegrown (prolactin) despite the imports.

Authors:  Senthil K Muthuswamy
Journal:  Genes Dev       Date:  2012-10-15       Impact factor: 11.361

10.  Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy.

Authors:  Prakash Radhakrishnan; Vashti C Bryant; Elizabeth C Blowers; Rajkumar N Rajule; Nagsen Gautam; Muhammad M Anwar; Ashley M Mohr; Paul M Grandgenett; Stephanie K Bunt; Jamie L Arnst; Subodh M Lele; Yazen Alnouti; Michael A Hollingsworth; Amarnath Natarajan
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.